Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver condition characterized by excessive fat accumulation in…
NAFLD
FDA Grants Breakthrough Therapy Designation to Madrigal’s Resmetirom
On April 18, 2023, Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its drug candidate resmetirom…